ImmunoPrecise Antibodies Ltd. - Asset Resilience Ratio
ImmunoPrecise Antibodies Ltd. (HYFT) has an Asset Resilience Ratio of 67.58% as of July 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check HYFT strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1997–2020)
This chart shows how ImmunoPrecise Antibodies Ltd.'s Asset Resilience Ratio has changed over time. See HYFT equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down ImmunoPrecise Antibodies Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is ImmunoPrecise Antibodies Ltd. worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $27.54 Million | 67.58% |
| Total Liquid Assets | $27.54 Million | 67.58% |
Asset Resilience Insights
- Very High Liquidity: ImmunoPrecise Antibodies Ltd. maintains exceptional liquid asset reserves at 67.58% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ImmunoPrecise Antibodies Ltd. Industry Peers by Asset Resilience Ratio
Compare ImmunoPrecise Antibodies Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for ImmunoPrecise Antibodies Ltd. (1997–2020)
The table below shows the annual Asset Resilience Ratio data for ImmunoPrecise Antibodies Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-04-30 | 0.00% | $104.00 | $27.26 Million | -15.51pp |
| 2016-04-30 | 15.51% | $214.14K | $1.38 Million | +15.22pp |
| 2010-04-30 | 0.30% | $16.20K | $5.47 Million | -0.17pp |
| 2009-04-30 | 0.47% | $32.50K | $6.93 Million | -4.44pp |
| 2008-04-30 | 4.91% | $253.25K | $5.16 Million | +3.85pp |
| 2007-04-30 | 1.06% | $58.75K | $5.56 Million | +0.83pp |
| 2006-04-30 | 0.22% | $9.00K | $4.05 Million | -0.59pp |
| 2001-04-30 | 0.81% | $9.40K | $1.16 Million | +0.24pp |
| 1999-04-30 | 0.57% | $9.40K | $1.66 Million | -6.17pp |
| 1998-04-30 | 6.73% | $197.32K | $2.93 Million | -50.56pp |
| 1997-04-30 | 57.30% | $2.22 Million | $3.88 Million | -- |
About ImmunoPrecise Antibodies Ltd.
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock ther… Read more